Effects of testosterone on cytokines and left ventricular remodeling following heart failure

Cellular Physiology and Biochemistry

Volumn 20, Issue 6, 2007, Pages 847-852

  Zhang, Yan Zhou ^a   Xing, Xiao Wen ^b   He, Ben ^a   Wang, Le Xin ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Heart failure; Myocardial infarction; Rats; Remodeling; Testosterone

Indexed keywords

CYTOKINE; GELATINASE B; HYDROXYPROLINE; INTERLEUKIN 10; MESSENGER RNA; PLACEBO; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TESTOSTERONE BLOOD LEVEL;

RATTUS;

ANIMALS; BODY WEIGHT; CYTOKINES; GENE EXPRESSION REGULATION; HEART FAILURE; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 35848940534     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110444     Document Type: Article

References (23)

1. Cleland JG, Khand A, Clark A: The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-626.
2. Ceconi C, Boraso A, Mele D, Guardigli R, Ferrari R: TNF alpha in patients with congestive heart failure. Basic Res Cardiol 2004;99:12-17.
3. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsay M, Rohde LE: Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
4. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H: Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220-225.
5. Aukrust P, Yndestad A, Damas JK, Gullestad L: Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. Autoimmun Rev 2004;3:221-227.
6. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH: The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004;89:3313-3318.
7. Pugh PJ, English KM, Jones TH, Channer KS: Testosterone: a natural tonic for the failing heart? Q J Med 2000;93:689-694.
8. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS: Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64.
9. Pugh PJ, Jones TH, Channer KS: Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909-915.
10. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS: Testosterone treatment for men with chronic heart failure. Heart 2004;90:446-447.
11. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M: Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829-1837.
12. Kaur K, Sharma AK, Singal PK: Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol - Heart Cir Physiol 2006;291:H106-13.
13. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
14. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287.
15. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF: Antitumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001;104:1094-1097.
16. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM: Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-1047.
17. Anker SD, Coats AJ: How to recover from renaissance? The significance of the results of, recover, renaissance, renewal and attach. Int J Cardiol 2002;86:123-130.
18. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-á, in patients with moderate-to-severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003;107:3133-3140.
19. Gullestad L, Aukrust P: Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005;95:17C-23C.
20. D'Agostino P, Milano S, Barbera C, Di Bella G, La Rosa M, Ferlazzo V: Sex hormones modulate inflammatory mediators produced by macrophages. Ann NY Acad Sci 1999;876:426-429.
21. Liva SM, Voskuhl RR: Testosterone acts directly on CD4+T lymphocytes to increase IL-10 production. J Immunol 2001;167:2060-2067.
22. Damas JK, Aukrust P, Ueland T, Odegaard A, Eiken HG, Gullestad L: Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes. Basic Res Cardiol 2001;96:345-352.
23. Miyamoto H, Altuwaijri S, Cai Y, Messing EM: Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinogen 2005;44:1-10.